This article is more than 5 years old. Information may no longer be current.

Video: NIAID Ebola vaccine well tolerated, immunogenic

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WILMINGTON, Del. — Julie Ledgerwood, DO, of the National Institute of Allergy and Infectious Diseases' Vaccine Research Center, reviews progress on development of the cAd3-EBO vaccine, presented today at the New Technologies, New Vaccines 2015 conference.

Ledgerwood said that the recombinant vaccine, which was rapidly advanced into Phase 1 clinical evaluation, was well tolerated and demonstrated immunogenicity.

Disclosure: Ledgerwood reports no relevant financial disclosures.